0001628280-23-029148.txt : 20230811 0001628280-23-029148.hdr.sgml : 20230811 20230811192620 ACCESSION NUMBER: 0001628280-23-029148 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230809 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stewart Murray CENTRAL INDEX KEY: 0001723450 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 231165760 MAIL ADDRESS: STREET 1: C/O NOVELION THERAPEUTICS INC. STREET 2: 1800-510 WEST GEORGIA STREET CITY: VANCOUVER STATE: A1 ZIP: V6B OM3 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 wk-form4_1691796370.xml FORM 4 X0508 4 2023-08-09 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001723450 Stewart Murray C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET, 4TH FLOOR BOSTON MA 02134 1 1 0 0 Interim Chief Medical Officer 0 Common Stock 2023-08-09 4 A 0 269893 0 A 276560 D Common Stock 2023-08-10 4 S 0 130056 1.06 D 146504 D Represents shares of common stock acquired upon acceleration of the vesting of a performance-based restricted stock unit grant. Represents nondiscretionary sale of shares required to be sold by the Reporting Person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Adam S. Mostafa, attorney-in-fact 2023-08-11